What’s new in critically-ill patients with antiphospholipid syndrome?

Authors

  • Marc Pineton de Chambrun 1. Sorbonne Université, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital La Pitié–Salpêtrière, Service de Médecine Intensive-Réanimation, Paris, France 2. Sorbonne Université, INSERM, UMRS_1166-ICAN, Institut de Cardiométabolisme et Nutrition (ICAN), Paris, France.  3. Sorbonne Université, APHP, Hôpital La Pitié–Salpêtrière Institut E3M, Service de Médecine Interne 2. Centre de Référence National Lupus Systémique, Syndrome des Anticorps Anti-phospholipides et Autres Maladies Auto-Immunes Systémiques Rares, Paris, France
  • Alexis Mathian Sorbonne Université, APHP, Hôpital La Pitié–Salpêtrière, Institut E3M, Service de Médecine Interne 2. Centre de Référence National Lupus Systémique, Syndrome des Anticorps Anti-phospholipides et Autres Maladies Auto-Immunes Systémiques Rares, Paris, France
  • Charles-Édouard Luyt 1. Sorbonne Université, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital La Pitié–Salpêtrière, Service de Médecine Intensive-Réanimation, Paris, France. 2. Sorbonne Université, INSERM, UMRS_1166-ICAN, Institut de Cardiométabolisme et Nutrition (ICAN)
  • Alain Combes 1. Sorbonne Université, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital La Pitié–Salpêtrière, Service de Médecine Intensive-Réanimation, Paris, France. 2. Sorbonne Université, INSERM, UMRS_1166-ICAN, Institut de Cardiométabolisme et Nutrition (ICAN)
  • Zahir Amoura Sorbonne Université, APHP, Hôpital La Pitié–Salpêtrière, Institut E3M, Service de Médecine Interne 2. Centre de Référence National Lupus Systémique, Syndrome des Anticorps Anti-phospholipides et Autres Maladies Auto-Immunes Systémiques Rares, Paris, France

DOI:

https://doi.org/10.37051/mir-00077

Keywords:

MANQUANTS, Antiphospholipid syndrome, Catastrophic antiphospholipid syndrome, Antiphospholipid antibodies, Lupus anticoagulant, Triple therapy

Abstract

 Antiphospholipid syndrome (APS) is a rare systemic autoimmune disease responsible for thrombotic events and obstetric morbidity in patients with persistent antiphospholipid autoantibodies (aPL). APS may be complicated by a “thrombotic storm” called the catastrophic antiphospholipid syndrome (CAPS), responsible for multiple organ failure and often requiring intensive care unit admission. CAPS was defined by an international consensus as the occurrence of: ≥ 3 organ/tissue/system involvement, developing in <7 days, with biopsy-proven small vessel occlusion in patients with persistent high aPL title. Thrombosis may develop in any organ, tissue or system. Small vessel occlusion is the hallmark of the classical presentation of the disease but large vessel thrombosis is also frequent. Thrombocytopenia is the most typical laboratory finding, occurring in >90% patients, occasionally below 20G/L, associated with anaemia although a true pattern of thrombotic microangiopathy is infrequent. Anticoagulation is the cornerstone treatment of CAPS, being the only one associated with better outcome in several cohorts. In case of life-threatening involvement, the treatment relies on a triple-therapy associating anticoagulation, high-dose corticosteroids and plasma exchange or intravenous immunoglobulins. One-year mortality of CAPS patients admitted to the intensive care unit is as high as 34%. Owing the rarity and the severity of the disease, the diagnosis and management of CAPS rely on a close cross-talk between intensivists and internal medicine physicians.

Image

Published

2021-08-23

How to Cite

Pineton de Chambrun, M., Mathian, A., Luyt, C.- Édouard, Combes, A., & Amoura, Z. (2021). What’s new in critically-ill patients with antiphospholipid syndrome?. Médecine Intensive Réanimation. https://doi.org/10.37051/mir-00077

Issue

Section

Update